SENS 111

Drug Profile

SENS 111

Alternative Names: Histamine H4 receptor antagonist - Palau Pharma; SENS111; UR-63325

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palau Pharma
  • Developer Palau Pharma; Sensorion
  • Class Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Vertigo
  • Preclinical Tinnitus
  • No development reported Asthma; Seasonal allergic rhinitis

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Vertigo in France (PO, Capsule)
  • 23 Mar 2017 Phase-II clinical trials in Vertigo in Czech Republic (PO) (EudraCT2016-003927-45)
  • 09 Mar 2017 Heads of Medicines Agencies authorises, via the Voluntary Harmonisation Procedure, a phase II trial in Vertigo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top